Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Sofosbuvir / Velpatasvir

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EU OKs paediatric use of Gilead's Epclusa
    EU OKs paediatric use of Gilead's Epclusa

    01 Sep 2020

    // Selina McKee PHARMATIMES

    http://www.pharmatimes.com/news/eu_oks_paediatric_use_of_gileads_epclusa_1347616

    Selina McKee PHARMATIMES
    01 Sep 2020
    Share Share
    Gilead Announces Presentation of More Than 40 Abstracts Extensive Liver Disease
    Gilead Announces Presentation of More Than 40 Abstracts Extensive Liver Disease

    25 Aug 2020

    // PRESS RELEASE

    https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gilead-announces-presentation-of-more-than-40-abstracts-from-extensive-liver-disease-programs-at-the-digital-international-liver-congress-2020

    PRESS RELEASE
    25 Aug 2020
    Share Share
    AbbVie’s HCV treatment receives first for shorter treatment cycle
    AbbVie’s HCV treatment receives first for shorter treatment cycle

    30 Sep 2019

    // B. Hargreaves IN-PHARMATECHNOLOGIST

    https://www.in-pharmatechnologist.com/Article/2019/09/30/AbbVie-receives-approval-HCV-treatment

    B. Hargreaves IN-PHARMATECHNOLOGIST
    30 Sep 2019
    Share Share
    FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier & Vosevi
    FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier & Vosevi

    29 Aug 2019

    // FDA

    https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and

    FDA
    29 Aug 2019
    Share Share
    FDA issues safety warning for newer hepatitis C drugs following patient deaths
    FDA issues safety warning for newer hepatitis C drugs following patient deaths

    28 Aug 2019

    // Jacob Bell BIOPHARMADIVE

    https://www.biopharmadive.com/news/fda-safety-warning-hepatitis-c-drugs-patient-deaths/561891/

    Jacob Bell BIOPHARMADIVE
    28 Aug 2019
    Share Share
    Particle Sciences Expands Controlled Substance Capabilities
    Particle Sciences Expands Controlled Substance Capabilities

    29 May 2019

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2019-05-29/particle-sciences-expands-controlled-substance-capabilities/

    CONTRACT PHARMA
    29 May 2019
    Share Share